Search Medical Condition
Please enter condition
Please choose location from dropdown

Suzhou City, China Clinical Trials

A listing of Suzhou City, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (93) clinical trials

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)

The primary objective of this study is to show superiority in the treatment of HMB of vilaprisan in subjects with uterine fibroids compared to placebo. The secondary objectives of this study are to additionally evaluate the efficacy and safety of vilaprisan in subjects with uterine fibroids.

Phase

3.13 miles

Learn More »

Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma

Primary Outcome Measures: Area under the curve (AUC) forTQB2303 and rituximab concentrations [ Time Frame: 85 days ] Secondary Outcome Measures: The Maximum Concentration (Cmax) of the TQB2303 and rituximab [ Time Frame: 85 days ] The area under the plasma concentration-time curve from 0 to inf (infinite) time (AUC0-); ...

Phase

3.13 miles

Learn More »

Postoperative Concurrent Chemoradiotherapy Combined With Endostar for High-risk Early Stage Cervical Cancer

This is a pilot phase 2, single arm study to assess the efficacy and safety of concurrent chemoradiotherapy combined with recombinant human endostatin (Endostar) in early stage cervical cancer patients with high risk factor(s). Postoperative pelvic radiotherapy starts 2-3 weeks after surgery. Intensity modulated radiotherapy (IMRT) is given five fractions ...

Phase

3.39 miles

Learn More »

CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor

The purpose of this study is to evaluate the safety and effectiveness of CAR-pNK cell immunotherapy in patients with MUC1 positive relapsed or refractory solid tumor.

Phase

9.68 miles

Learn More »

Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with CD19 positive relapsed or refractory Leukemia and Lymphoma.

Phase

9.68 miles

Learn More »

PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma

The purpose of this study is to evaluate the safety and optimal dose of PCAR-119 in patients who are going to receive stem cell transplantation but without available treatment to achieve complete remission prior to the transplant. In addition, some patients who enroll to other CD19-CAR-T cell therapy trials might ...

Phase

9.68 miles

Learn More »

CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML

PRIMARY OBJECTIVES: Determine the safety and feasibility of the chimeric antigen receptor NK92 cells transduced with the anti-CD33 vector (referred to as anti-CD33 CAR-NK cells). SECONDARY OBJECTIVES: I. For patients with detectable disease, measure anti-leukemia response due to anti-CD33 CAR-NK cell infusions. II. For patients with stored or accessible leukemia ...

Phase

9.68 miles

Learn More »

Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor

The purpose of this study is to determine whether autologous T cells bearing chimeric antigen receptor that can specifically recognize (Mucin 1) MUC1 is safe and effective for patients with relapsed or refractory solid tumor.

Phase

9.68 miles

Learn More »

CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor

The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with MUC1 positive relapsed or refractory solid tumor.

Phase

9.68 miles

Learn More »

CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma

The purpose of this study is to evaluate the safety and effectiveness of CAR-pNK cell immunotherapy in patients with CD7 positive relapsed or refractory Leukemia and Lymphoma.

Phase

9.68 miles

Learn More »